APO Research
Talk to an analyst

APO RESEARCH · REPORT

Waldenstrom Macroglobulinemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Waldenstrom Macroglobulinemia Therapeutics Industry Growth and Trends Forecast to 2032

26 December 2025109 pages

Choose your research edition.

Industry ResearchWaldenstrom Macroglobulinemia Therapeutics Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Waldenstrom Macroglobulinemia Therapeutics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Waldenstrom Macroglobulinemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Waldenstrom Macroglobulinemia Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Waldenstrom Macroglobulinemia Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Waldenstrom Macroglobulinemia Therapeutics include Merck KGaA, Millennium Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Incyte Corporation, IGF Oncology, LLC., Idera Pharmaceuticals, Inc., Hutchison MediPharma Limited, Gilead Sciences, Inc. and Genmab A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Waldenstrom Macroglobulinemia Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Waldenstrom Macroglobulinemia Therapeutics market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Waldenstrom Macroglobulinemia Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Waldenstrom Macroglobulinemia Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Waldenstrom Macroglobulinemia Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Waldenstrom Macroglobulinemia Therapeutics Market by Company

Merck KGaA

Millennium Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Incyte Corporation

IGF Oncology, LLC.

Idera Pharmaceuticals, Inc.

Hutchison MediPharma Limited

Gilead Sciences, Inc.

Genmab A/S

Genentech, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

BeiGene(Beijing) Co.,Ltd

Waldenstrom Macroglobulinemia Therapeutics Segment by Type

CB-839

DI-B4

FV-162

Entospletinib

Copanlisib Hydrochloride

Everolimus

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Application

Clinic

Hospital

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Waldenstrom Macroglobulinemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Waldenstrom Macroglobulinemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Waldenstrom Macroglobulinemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Waldenstrom Macroglobulinemia Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Waldenstrom Macroglobulinemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CB-839 Table 2. Major Company of DI-B4 Table 3. Major Company of FV-162 Table 4. Major Company of Entospletinib Table 5. Major Company of Copanlisib Hydrochloride Table 6. Major Company of Everolimus Table 7. Major Company of Others Table 8. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 10. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type (2021-2026) Table 11. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 12. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type (2021-2026) Table 13. Global Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2026) & (US$/Unit) Table 14. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 15. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type (2027-2032) Table 16. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (US$ Million) Table 17. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type (2027-2032) Table 18. Global Waldenstrom Macroglobulinemia Therapeutics Price by Type (2027-2032) & (US$/Unit) Table 19. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 20. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 22. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 24. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 26. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 28. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 29. Waldenstrom Macroglobulinemia Therapeutics Industry Trends Table 30. Waldenstrom Macroglobulinemia Therapeutics Industry Drivers Table 31. Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges Table 32. Waldenstrom Macroglobulinemia Therapeutics Industry Restraints Table 33. Global Waldenstrom Macroglobulinemia Therapeutics Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Company (2021-2026) Table 35. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Company (2021-2026) & (W Units) Table 36. Global Waldenstrom Macroglobulinemia Therapeutics Sales Share by Company (2021-2026) Table 37. Global Waldenstrom Macroglobulinemia Therapeutics Market Price by Company (2021-2026) & (US$/Unit) Table 38. Global Waldenstrom Macroglobulinemia Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Waldenstrom Macroglobulinemia Therapeutics Major Company Production Sites and Headquarters Table 40. Global Waldenstrom Macroglobulinemia Therapeutics Company, Product Type & Application Table 41. Global Waldenstrom Macroglobulinemia Therapeutics Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Waldenstrom Macroglobulinemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026) & (W Units) Table 46. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Region (2021-2026) Table 47. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026) & (US$ Million) Table 48. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Region (2021-2026) Table 49. Global Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 50. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2027-2032) & (W Units) Table 51. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Region (2027-2032) Table 52. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2027-2032) & (US$ Million) Table 53. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Region (2027-2032) Table 54. Global Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 55. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 57. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application (2021-2026) Table 58. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 59. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application (2021-2026) Table 60. Global Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2026) & (US$/Unit) Table 61. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 62. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application (2027-2032) Table 63. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (US$ Million) Table 64. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application (2027-2032) Table 65. Global Waldenstrom Macroglobulinemia Therapeutics Price by Application (2027-2032) & (US$/Unit) Table 66. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 67. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 69. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 71. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 73. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 75. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 76. Merck KGaA Company Information Table 77. Merck KGaA Business Overview Table 78. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 80. Merck KGaA Recent Development Table 81. Millennium Pharmaceuticals, Inc. Company Information Table 82. Millennium Pharmaceuticals, Inc. Business Overview Table 83. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 85. Millennium Pharmaceuticals, Inc. Recent Development Table 86. Karyopharm Therapeutics, Inc. Company Information Table 87. Karyopharm Therapeutics, Inc. Business Overview Table 88. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 90. Karyopharm Therapeutics, Inc. Recent Development Table 91. Incyte Corporation Company Information Table 92. Incyte Corporation Business Overview Table 93. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 95. Incyte Corporation Recent Development Table 96. IGF Oncology, LLC. Company Information Table 97. IGF Oncology, LLC. Business Overview Table 98. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 100. IGF Oncology, LLC. Recent Development Table 101. Idera Pharmaceuticals, Inc. Company Information Table 102. Idera Pharmaceuticals, Inc. Business Overview Table 103. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 105. Idera Pharmaceuticals, Inc. Recent Development Table 106. Hutchison MediPharma Limited Company Information Table 107. Hutchison MediPharma Limited Business Overview Table 108. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 110. Hutchison MediPharma Limited Recent Development Table 111. Gilead Sciences, Inc. Company Information Table 112. Gilead Sciences, Inc. Business Overview Table 113. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 115. Gilead Sciences, Inc. Recent Development Table 116. Genmab A/S Company Information Table 117. Genmab A/S Business Overview Table 118. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 120. Genmab A/S Recent Development Table 121. Genentech, Inc. Company Information Table 122. Genentech, Inc. Business Overview Table 123. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 125. Genentech, Inc. Recent Development Table 126. Celgene Corporation Company Information Table 127. Celgene Corporation Business Overview Table 128. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 130. Celgene Corporation Recent Development Table 131. Calithera Biosciences, Inc. Company Information Table 132. Calithera Biosciences, Inc. Business Overview Table 133. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 135. Calithera Biosciences, Inc. Recent Development Table 136. BeiGene(Beijing) Co.,Ltd Company Information Table 137. BeiGene(Beijing) Co.,Ltd Business Overview Table 138. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 140. BeiGene(Beijing) Co.,Ltd Recent Development Table 141. North America Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 142. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 143. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2026) Table 144. North America Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032) & (W Units) Table 145. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 146. North America Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 148. North America Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2021-2026) Table 149. North America Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America Waldenstrom Macroglobulinemia Therapeutics Market Share Forecast by Country (2027-2032) Table 151. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 152. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 153. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2026) Table 154. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032) & (W Units) Table 155. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 156. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2021-2026) Table 159. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe Waldenstrom Macroglobulinemia Therapeutics Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 163. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032) & (W Units) Table 165. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2021-2026) Table 169. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Share Forecast by Country (2027-2032) Table 171. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 172. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 173. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2026) Table 174. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032) & (W Units) Table 175. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2021-2026) Table 179. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 183. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032) & (W Units) Table 185. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2021-2026) Table 189. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Waldenstrom Macroglobulinemia Therapeutics Distributors List Table 194. Waldenstrom Macroglobulinemia Therapeutics Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Waldenstrom Macroglobulinemia Therapeutics Image Figure 2. Global Waldenstrom Macroglobulinemia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Waldenstrom Macroglobulinemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Waldenstrom Macroglobulinemia Therapeutics Sales (2021-2032) & (W Units) Figure 5. CB-839 Image Figure 6. Global CB-839 Sales YoY Growth (2021-2032) & (W Units) Figure 7. DI-B4 Image Figure 8. Global DI-B4 Sales YoY Growth (2021-2032) & (W Units) Figure 9. FV-162 Image Figure 10. Global FV-162 Sales YoY Growth (2021-2032) & (W Units) Figure 11. Entospletinib Image Figure 12. Global Entospletinib Sales YoY Growth (2021-2032) & (W Units) Figure 13. Copanlisib Hydrochloride Image Figure 14. Global Copanlisib Hydrochloride Sales YoY Growth (2021-2032) & (W Units) Figure 15. Everolimus Image Figure 16. Global Everolimus Sales YoY Growth (2021-2032) & (W Units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 19. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Type 2025 VS 2032 Figure 21. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type in 2025 Figure 22. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type in 2025 Figure 23. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type in 2025 Figure 24. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type in 2025 Figure 27. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Waldenstrom Macroglobulinemia Therapeutics Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 35. Hospital Image Figure 36. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 39. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Application 2025 VS 2032 Figure 41. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application in 2025 Figure 42. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application in 2025 Figure 43. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application in 2025 Figure 44. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application in 2025 Figure 47. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application in 2025 Figure 51. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. North America Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Waldenstrom Macroglobulinemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Waldenstrom Macroglobulinemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 68. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Waldenstrom Macroglobulinemia Therapeutics Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Waldenstrom Macroglobulinemia Therapeutics Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • CB-839
  • DI-B4
  • FV-162
  • Entospletinib
  • Copanlisib Hydrochloride
  • Everolimus
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Karyopharm Therapeutics, Inc.
  • Incyte Corporation
  • IGF Oncology, LLC.
  • Idera Pharmaceuticals, Inc.
  • Hutchison MediPharma Limited
  • Gilead Sciences, Inc.
  • Genmab A/S
  • Genentech, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • BeiGene(Beijing) Co.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Waldenstrom Macroglobulinemia Therapeutics Market by Type
  6. 1.3.1 CB-839
  7. 1.3.2 DI-B4
  8. 1.3.3 FV-162
  9. 1.3.4 Entospletinib
  10. 1.3.5 Copanlisib Hydrochloride
  11. 1.3.6 Everolimus
  12. 1.3.7 Others
  13. 1.4 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
  14. 1.4.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Waldenstrom Macroglobulinemia Therapeutics Industry Trends
  2. 2.2 Waldenstrom Macroglobulinemia Therapeutics Industry Drivers
  3. 2.3 Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Waldenstrom Macroglobulinemia Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2026)
  2. 3.2 Global Top Players by Waldenstrom Macroglobulinemia Therapeutics Sales (2021-2026)
  3. 3.3 Global Top Players by Waldenstrom Macroglobulinemia Therapeutics Price (2021-2026)
  4. 3.4 Global Waldenstrom Macroglobulinemia Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Waldenstrom Macroglobulinemia Therapeutics Major Company Production Sites & Headquarters
  6. 3.6 Global Waldenstrom Macroglobulinemia Therapeutics Company, Product Type & Application
  7. 3.7 Global Waldenstrom Macroglobulinemia Therapeutics Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Waldenstrom Macroglobulinemia Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Waldenstrom Macroglobulinemia Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Waldenstrom Macroglobulinemia Therapeutics Tier 1, Tier 2, and Tier 3
4 Waldenstrom Macroglobulinemia Therapeutics Regional Status and Outlook
  1. 4.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size by Region
  3. 4.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Region
  7. 4.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Waldenstrom Macroglobulinemia Therapeutics by Application
  1. 5.1 Waldenstrom Macroglobulinemia Therapeutics Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
  6. 5.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck KGaA
  2. 6.1.1 Merck KGaA Company Information
  3. 6.1.2 Merck KGaA Business Overview
  4. 6.1.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  6. 6.1.5 Merck KGaA Recent Developments
  7. 6.2 Millennium Pharmaceuticals, Inc.
  8. 6.2.1 Millennium Pharmaceuticals, Inc. Company Information
  9. 6.2.2 Millennium Pharmaceuticals, Inc. Business Overview
  10. 6.2.3 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  12. 6.2.5 Millennium Pharmaceuticals, Inc. Recent Developments
  13. 6.3 Karyopharm Therapeutics, Inc.
  14. 6.3.1 Karyopharm Therapeutics, Inc. Company Information
  15. 6.3.2 Karyopharm Therapeutics, Inc. Business Overview
  16. 6.3.3 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  18. 6.3.5 Karyopharm Therapeutics, Inc. Recent Developments
  19. 6.4 Incyte Corporation
  20. 6.4.1 Incyte Corporation Company Information
  21. 6.4.2 Incyte Corporation Business Overview
  22. 6.4.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  24. 6.4.5 Incyte Corporation Recent Developments
  25. 6.5 IGF Oncology, LLC.
  26. 6.5.1 IGF Oncology, LLC. Company Information
  27. 6.5.2 IGF Oncology, LLC. Business Overview
  28. 6.5.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  30. 6.5.5 IGF Oncology, LLC. Recent Developments
  31. 6.6 Idera Pharmaceuticals, Inc.
  32. 6.6.1 Idera Pharmaceuticals, Inc. Company Information
  33. 6.6.2 Idera Pharmaceuticals, Inc. Business Overview
  34. 6.6.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  36. 6.6.5 Idera Pharmaceuticals, Inc. Recent Developments
  37. 6.7 Hutchison MediPharma Limited
  38. 6.7.1 Hutchison MediPharma Limited Company Information
  39. 6.7.2 Hutchison MediPharma Limited Business Overview
  40. 6.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  42. 6.7.5 Hutchison MediPharma Limited Recent Developments
  43. 6.8 Gilead Sciences, Inc.
  44. 6.8.1 Gilead Sciences, Inc. Company Information
  45. 6.8.2 Gilead Sciences, Inc. Business Overview
  46. 6.8.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  48. 6.8.5 Gilead Sciences, Inc. Recent Developments
  49. 6.9 Genmab A/S
  50. 6.9.1 Genmab A/S Company Information
  51. 6.9.2 Genmab A/S Business Overview
  52. 6.9.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  54. 6.9.5 Genmab A/S Recent Developments
  55. 6.10 Genentech, Inc.
  56. 6.10.1 Genentech, Inc. Company Information
  57. 6.10.2 Genentech, Inc. Business Overview
  58. 6.10.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  60. 6.10.5 Genentech, Inc. Recent Developments
  61. 6.11 Celgene Corporation
  62. 6.11.1 Celgene Corporation Company Information
  63. 6.11.2 Celgene Corporation Business Overview
  64. 6.11.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  66. 6.11.5 Celgene Corporation Recent Developments
  67. 6.12 Calithera Biosciences, Inc.
  68. 6.12.1 Calithera Biosciences, Inc. Company Information
  69. 6.12.2 Calithera Biosciences, Inc. Business Overview
  70. 6.12.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  72. 6.12.5 Calithera Biosciences, Inc. Recent Developments
  73. 6.13 BeiGene(Beijing) Co.,Ltd
  74. 6.13.1 BeiGene(Beijing) Co.,Ltd Company Information
  75. 6.13.2 BeiGene(Beijing) Co.,Ltd Business Overview
  76. 6.13.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  78. 6.13.5 BeiGene(Beijing) Co.,Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country
  2. 7.1.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026)
  4. 7.1.3 North America Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032)
  5. 7.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  6. 7.2.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026)
  8. 7.2.3 North America Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country
  2. 8.1.1 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026)
  4. 8.1.3 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  6. 8.2.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026)
  8. 8.2.3 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country
  2. 9.1.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  6. 9.2.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Waldenstrom Macroglobulinemia Therapeutics Sales by Country
  2. 10.1.1 South America Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026)
  4. 10.1.3 South America Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032)
  5. 10.2 South America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  6. 10.2.1 South America Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026)
  8. 10.2.3 South America Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country
  2. 11.1.1 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  6. 11.2.1 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Waldenstrom Macroglobulinemia Therapeutics Value Chain Analysis
  2. 12.1.1 Waldenstrom Macroglobulinemia Therapeutics Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Waldenstrom Macroglobulinemia Therapeutics Production Mode & Process
  7. 12.2 Waldenstrom Macroglobulinemia Therapeutics Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Waldenstrom Macroglobulinemia Therapeutics Distributors
  10. 12.2.3 Waldenstrom Macroglobulinemia Therapeutics Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst